Overview

Study of REGN2810 Prior to Surgery in Patients With Advanced-Stage, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck

Status:
Recruiting

Trial end date:
2020-01-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if giving REGN2810 before standard of care surgery and radiation can help to control advanced cutaneous squamous cell carcinoma (cSCC). The safety of this drug will also be studied. Receiving REGN2810 in this study will not change your standard of care treatment (radiation and surgery). Researchers think that REGN2810 may help to control (or shrink) the cancer before receiving surgery/radiation, but it is not likely to help control the disease after surgery/radiation. This is an investigational study. REGN2810 is not FDA approved or commercially available. It is currently being used for research purposes only. The study doctor can explain how the study drug is designed to work. Up to 22 participants will take part in this study. All will be enrolled at MD Anderson.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Regeneron Pharmaceuticals